Drug Trial Radar · NCT07038447
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
52
Planned (sponsor's estimate)
Start
Jul 2, 2025
Primary completion
Sep 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases. The primary objectives of this study are: Phase 1a: To evaluate the safety and tolerability of KITE-363 in participants with autoimmune disease. To determine the recommended dose for Phase 1b. Phase 1b: To evaluate the safety and efficacy of KITE-363 in participants with autoimmune disease.
Conditions
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathy
Interventions
KITE-363Biological
A single infusion of CAR-transduced autologous T cells administered intravenously
FludarabineDrug
Administered intravenously
CyclophosphamideDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363Time frame: Up to 2 years
- Phase 1b: All Cohorts Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 2 years
- Phase 1b: Systemic lupus erythematosus (SLE): Proportion of participants meeting DORIS remission and Lupus low Disease Activity State (LLDAS) criteria at Month 6Time frame: Month 6
- Phase 1b: Lupus Nephritis (LN): Proportion of Participants Meeting DORIS RemissionTime frame: Month 6
- Phase 1b: LN: Proportion of Participants Achieving a Complete Renal Response at Month 6Time frame: Month 6
- Phase 1b: Systemic Sclerosis (SSc) Cohort: Proportion of Participants With Improvement in Disease Activity by the Revised Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (rCRISS) at Month 6Time frame: Month 6
- Phase 1b: Idiopathic Inflammatory Myopathy (IIM): Proportions of Participants Meeting European League Against Rheumatism (EULAR)-American College of Rheumatology (ACR) Moderate and Major response 2016 Criteria in Total Improvement Score (TIS) at Month 6Time frame: Month 6
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Stanford University
Stanford, California
Tampa General Hospital Cancer Institute
Tampa, Florida
Icahn School of Medicine at Mount Sinai
New York, New York
Concord Repatriation General Hospital
Syndey, New South Wales, Australia
St Vincent's Hospital
Fitzroy, Victoria, Australia
Jewish General Hospital
Montreal, Canada
The Ottawa Hospital, General Campus
Ottawa, Canada
Seoul National University
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.